Drugs / TD-1607
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01949103 | Oct 2013 → Jun 2014 | bacterial infectious disease | Theravance Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT01791049 | Apr → Aug 2013 | gram-positive bacterial infections | Theravance Biopharma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TD-1607 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01791049 ↗ |
| Modality | Other / unclassified | “a Glycopeptide-Cephalosporin Heterodimer Gram-Positive Antibiotic” NCT01791049 ↗ |
| Route | Intravenous | “administered intravenously as single doses” NCT01791049 ↗ |